Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

NCT06472388 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Progression
Neuroendocrine Tumor Grade 1
Neuroendocrine Tumor Grade 2
Neuroendocrine Tumor of Pancreas
Neuroendocrine Tumor of the Lung
Neuroendocrine Tumor Carcinoid

Interventions

DRUG: Everolimus 5 MG

Sponsor

AC Camargo Cancer Center